市場調査レポート

商品コード

1619188

肺がん市場規模、シェア、成長分析、診断・治療別、適応症別、最終用途別、地域別 - 産業別予測、2024～2031年

Lung Cancer Market Size, Share, Growth Analysis, By Diagnostics & Therapy (Diagnostics, Therapy), By Indication (Non-Small Cell Lung Cancer, Small Cell Lung Cancer), By End-Use, By Region - Industry Forecast 2024-2031

出版日: 2024年12月18日
発行: SkyQuest
ページ情報: 英文 157 Pages
納期: 3～5営業日

価格

PDF & Excel (Single User License)

USD 5,300 760,921円

レポートPDF・Excelを1 名様のみがご利用頂けるライセンスです。PDF・Excell内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します

PDF & Excel (Multiple User License)

USD 6,200 890,134円

レポートPDF・Excel2-5名様までがご利用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

PDF & Excel (Enterprise License)

USD 7,100 1,019,347円

レポートPDF・Excelを同一企業に所属の全世界の方にご使用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=143.57円

全表示
概要
目次

概要

サンプル依頼リストに入れる

肺がんの世界市場規模は2022年に294億5,000万米ドルと評価され、2023年の326億6,000万米ドルから2031年には747億3,000万米ドルに成長し、予測期間（2024～2031年）のCAGRは10.9%で成長する見通しです。

肺がんの世界市場は、公衆衛生に重大な課題をもたらす流行している致死的な疾患の診断、治療、管理に焦点を当てた重要なヘルスケア分野です。主に喫煙、環境汚染物質、遺伝的要因に起因する罹患率の上昇に伴い、標的療法や免疫療法などの診断・治療オプションの革新的進歩が市場を後押ししています。従来の化学療法から個別化された効果的な治療への顕著なシフトが患者の転帰を向上させる一方、早期発見と予防対策への意識の高まりが市場の成長を後押ししています。治療コストやアクセスのしやすさなどの課題にもかかわらず、人工知能やビッグデータの統合と並行して進行中の研究は、診断と治療戦略に革命を起こすことを約束し、この進化する市場において患者ケアの改善と成長の大きな可能性を示しています。

市場概要
診断
- 気管支鏡検査
- TTNA
- イメージング
- 腫瘍バイオマーカー検査
- インサイチューハイブリダイゼーション
- その他
治療
- 非侵襲的
- 免疫療法
- 標的療法
- 低侵襲
- 高周波アブレーション
- マイクロ波アブレーション
- 熱凝固/凍結療法

肺がん市場規模：適応症別およびCAGR（2024～2031年）

市場概要
非スモールセル肺がん
スモールセル肺がん

肺がん市場規模：最終用途別およびCAGR（2024～2031年）

市場概要
病院
診断検査室
画像診断センター
学術界
専門クリニック

肺がん市場規模およびCAGR（2024～2031年）

北米
- 米国
- カナダ
欧州
- ドイツ
- スペイン
- フランス
- 英国
- イタリア
- その他欧州地域
アジア太平洋地域
- 中国
- インド
- 日本
- 韓国
- その他アジア太平洋地域
ラテンアメリカ
- ブラジル
- その他ラテンアメリカ地域
中東・アフリカ
- GCC諸国
- 南アフリカ
- その他中東・アフリカ

競合情報

上位5社の比較
主要企業の市場ポジショニング（2023年）
主な市場企業が採用した戦略
市場の最近の動向
企業の市場シェア分析（2023年）
主要企業の企業プロファイル
- 会社概要
- 製品ポートフォリオ分析
- セグメント別シェア分析
- 収益の前年比比較（2021～2023年）

主要企業プロファイル

F. Hoffmann-La Roche（Switzerland）
AstraZeneca（UK）
Sanofi（France）
Pfizer, Inc.（US）
Bristol-Myers Squibb Company（US）
Sysmex Corporation（Japan）
Thermo Fisher Scientific（US）
Qiagen（Germany）
Janssen Pharmaceuticals（US）
Quest Diagnostics（US）
Takeda Pharmaceutical Company（Japan）
Novartis AG（Switzerland）
Eli Lilly & Company（US）
Merck & Co., Inc.（US）
Boehringer Ingelheim（Germany）
Merck KGaA（EMD Serono）（Germany）
AbbVie（US）
Astellas Pharma（Japan）
GlaxoSmithKline（UK）
Johnson & Johnson（US）

結論と推奨事項

Product Code: SQMIG35D2167

Global Lung Cancer Market size was valued at USD 29.45 billion in 2022 and is poised to grow from USD 32.66 billion in 2023 to USD 74.73 billion by 2031, growing at a CAGR of 10.9% during the forecast period (2024-2031).

The global lung cancer market represents a vital healthcare sector focused on diagnosing, treating, and managing a prevalent and lethal disease that poses significant public health challenges. With rising incidences primarily attributed to smoking, environmental pollutants, and genetic factors, the market is fueled by innovative advancements in diagnostic and therapeutic options, such as targeted therapies and immunotherapies. A notable shift from traditional chemotherapy to personalized and effective treatments enhances patient outcomes, while increased awareness of early detection and preventative measures drives market growth. Despite challenges like treatment costs and accessibility, ongoing research, alongside the integration of artificial intelligence and big data, promises to revolutionize diagnosis and therapeutic strategies, showcasing significant potential for improved patient care and growth within this evolving market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Lung Cancer market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Lung Cancer Market Segmental Analysis

Global Lung Cancer Market is segmented by diagnostics, indication, end-use and region. Based on diagnostics, the market is segmented into diagnostics and therapy. Based on indication, the market is segmented into non-small cell lung cancer and small cell lung cancer. Based on end-use, the market is segmented into hospitals, diagnostic laboratories, diagnostic imaging centers, academia, specialty clinics, and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Lung Cancer Market

A significant catalyst for the global lung cancer market is the relentless progress in medical research and technology. The growing comprehension of lung cancer biology, alongside breakthroughs in diagnostic tools, targeted therapies, immunotherapies, and precision medicine, is propelling market growth. These innovations not only introduce novel treatment alternatives but also enhance patient outcomes and facilitate early detection. The shift towards personalized treatment strategies allows healthcare providers to tailor interventions to individual patient profiles, further driving the demand for advanced lung cancer therapies. Consequently, these technological advancements are pivotal in shaping the future landscape of the lung cancer treatment market.

Restraints in the Global Lung Cancer Market

One of the main challenges facing the global lung cancer market is the exorbitant cost associated with treatments. Patients often confront substantial financial burdens due to the high prices of lung cancer therapies, such as targeted treatments and immunotherapies. This issue can severely limit patient access to these advanced options, particularly in areas with limited healthcare resources or insufficient insurance coverage. Consequently, the overall affordability and accessibility of lung cancer treatments create significant obstacles that can impede the market's growth and hinder the provision of equitable care to patients, ultimately affecting the broader adoption of essential therapies.

Market Trends of the Global Lung Cancer Market

The global lung cancer market is witnessing a significant trend towards precision medicine and targeted therapies, driven by advancements in genomic research and molecular characterization of tumors. This shift fosters the development of personalized treatment regimens that specifically address genetic mutations and biomarkers unique to each patient. As healthcare systems prioritize improved treatment outcomes and reduced adverse effects, the demand for tailored therapies is surging. Furthermore, the integration of molecular profiling techniques is enhancing the efficacy of treatments, promising better patient care and prognosis. This evolution not only reshapes therapeutic approaches but also amplifies the potential for innovation in lung cancer management globally.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2023
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Technology Analysis
Regulatory Analysis
Patent Analysis
Case Study Analysis
Pipeline Analysis

Global Lung Cancer Market Size by Diagnostics & Therapy & CAGR (2024-2031)

Market Overview
Diagnostics
- Bronchoscopy
- TTNA
- Imaging
- Tumor Biomarker Test
- In Situ Hybridization
- Others
Therapy
- Non-Invasive
- Immunotherapy
- Targeted Therapy
- Minimally Invasive
- Radiofrequency Ablation
- Microwave Ablation
- Thermal/Cryoablation

Global Lung Cancer Market Size by Indication & CAGR (2024-2031)

Market Overview
Non-Small Cell Lung Cancer
Small Cell Lung Cancer

Global Lung Cancer Market Size by End-Use & CAGR (2024-2031)

Market Overview
Hospitals
Diagnostic Laboratories
Diagnostic Imaging Centers
Academia
Specialty Clinics

Global Lung Cancer Market Size & CAGR (2024-2031)

North America (Diagnostics & Therapy, Indication, End-Use)
- USA
- Canada
Europe (Diagnostics & Therapy, Indication, End-Use)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Diagnostics & Therapy, Indication, End-Use)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Diagnostics & Therapy, Indication, End-Use)
- Brazil
- Rest of Latin America
Middle East & Africa (Diagnostics & Therapy, Indication, End-Use)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2023
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

F. Hoffmann-La Roche (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol-Myers Squibb Company (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sysmex Corporation (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Thermo Fisher Scientific (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Qiagen (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Janssen Pharmaceuticals (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Quest Diagnostics (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly & Company (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Boehringer Ingelheim (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck KGaA (EMD Serono) (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Astellas Pharma (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments